News & Publications

Latest from Callio

Announcements, clinical milestones, and scientific presentations from our dual-payload ADC programs.

News

Callio Therapeutics Wins Best New ADC Drug Developer at the 13th World ADC Awards, Presents Across Five Sessions at World ADC San Diego

Callio Therapeutics wins Best New ADC Drug Developer at the 13th World ADC Awards and presents on dual-payload ADCs at World ADC San Diego 2026.

Read More →

News

Callio Therapeutics Appoints Chris Hassig, PhD, as Chief Scientific Officer

Industry veteran brings more than two decades of oncology drug discovery leadership to advance Callio's dual-payload ADC pipeline

Read More →

News

Callio Therapeutics Appoints Zachary Hornby as Chief Executive Officer

Callio Therapeutics appoints Zachary Hornby as Chief Executive Officer, with Piers Ingram, PhD, transitioning to Senior Advisor.

Read More →

Publication

ASCO 2026: Phase 1/2 Study of CLIO-8221, a HER2-targeted, dual-payload exatecan and ATR inhibitor antibody-drug conjugate (ADC) in patients with advanced HER2-expressing solid tumors

Trials in Progress poster at ASCO highlights the Phase 1 trial design of CLIO-8221.

View Publication →

News

Callio Therapeutics to Present Phase 1 Trial Design of CLIO-8221, Novel Dual-Payload ADC, at ASCO 2026

At ASCO 2026, Callio Therapeutics will present a trials in progress poster on May 30, 2026, highlighting the Phase 1 trial design of CLIO-8221

Read More →

Publication

AACR 2026: Development of CLIO-8221: A clinical stage HER2-targeted dual-payload ADC to address ADC resistance

CLIO-8221, a novel, first-in-class dual-payload antibody-drug conjugate targets HER2 to co-deliver Topo1i and ATRi payloads to overcome Topo1i resistance.

View Publication →

Careers

Join Us

There are no open positions at this time. Follow us on LinkedIn for updates on future opportunities.

General Inquiries

Contact Us

Careers

Join Us

There are no open positions at this time. Follow us on LinkedIn for updates on future opportunities.

General Inquiries

Contact Us